[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 6.625 6.25 7.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.0 -3.7 -0.8 - 30

Collagen Solutions Share Discussion Threads

Showing 651 to 673 of 850 messages
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
DateSubjectAuthorDiscuss
25/6/2019
09:53
Should build into results you would think.
ileeman
17/6/2019
12:00
Chart looking promising. I bought a few. GL
horneblower
10/6/2019
19:44
The Collagen Solutions presentation from our recent London company seminar can be found in our members area here: hTTps://sharesoc.ning.com/xn/detail/6389471:Comment:53165 To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps://www.sharesoc.org/membership/ Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://www.sharesoc.org/contact-us/
sharesoc
07/6/2019
15:14
Wow,having a nice share price run today.
martintino
28/5/2019
16:37
Just to let you know, Collagen present at our Manchester growth company seminar on the 4th June, which may be of interest to current shareholders and potential investors. More details here: hTTps://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-4-june-2019/
sharesoc
22/5/2019
12:19
Collagen Solutions present at our Manchester growth company seminar on the 4th June, which may be of interest to current shareholders and potential investors. More details here: hTTps://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-4-june-2019/
sharesoc
20/5/2019
13:18
Views on recent news? It reads to me that we got CE mark... well jamal comments wise
moontheloon
10/4/2019
13:22
Thanks for the link to a very positive and interesting podcast.
martintino
10/4/2019
08:33
More than Money: Collagen Solutions 09/04/2019 · #Collagen #Solutions (#COS) https://twitter.com/smallcappick/status/1115880452605321218
newtothisgame3
10/4/2019
06:15
Scots biotech firm on course to beat forecasts #COS https://twitter.com/smallcappick/status/1115845651772989440
newtothisgame3
10/4/2019
06:12
Financial turnaround for Glasgow’s #Collagen #Solutions #COS https://twitter.com/smallcappick/status/1115844782511853570
newtothisgame3
05/4/2019
16:52
Anyone any idea which Brett Gordon is building a stake - Goem from <3% to over 4% in 2 days - Some 3.2 million extra share. Not insigificant and much more than marked as trades tracked by ADVFN - Dark pool or NEX or outside the market? Thoughts?
pugugly
03/4/2019
11:54
Definetly some Bed and ISA action going on with COS imo. suspect there has been for a while here. Any thoughts?
martintino
28/2/2019
14:58
https://www.youtube.com/watch?v=mcVVgJIWGVU&t=26s Update from tuesday. 51 mins onwards is Jamal of COS
martintino
27/2/2019
12:32
Any comment updates from investor evening ?
moontheloon
18/2/2019
09:12
Unfortunately I will miss this one as will be in the US, it would be nice it if coincided with news on CE approval for ChondroMimetic Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that Jamal Rushdy will be presenting at an investor evening hosted by Hardman & Co on Tuesday, 26 February at DAC Beachcroft, 100 Fetter Lane, London EC4A 1BN. The event provides an opportunity for investors to hear about the progress being made by the Company and the potential for its own products going forward. Jamal Rushdy will give a 15 minute presentation followed by a 10 minute Q&A session. Registration is from 5.30pm for a prompt start at 6.00pm.
timbo003
01/2/2019
07:40
Collagen Solutions PLC ChondroMimeticĀ® UpdateSource:Ā UK Regulatory (RNS & others)TIDMCOSRNS Number : 5866OCollagen Solutions PLC31 January 201931 January 2019Collagen Solutions plc("Collagen Solutions", the "Company" or the "Group")ChondroMimetic(R) UpdateDistribution Agreement with Indonesian Partner and Update on CE Mark ProcessCollagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a new license and distribution agreement for ChondroMimetic(R) with an Indonesian partner, PT Rajawali Mutiara Sejahtera ("Rajawali Medika"). Rajawali Medika will collaborate with Collagen Solutions to obtain regulatory approval and launch ChondroMimetic(R) in Indonesia with the potential to expand to several other South East Asian countries. Financial terms of the agreement were not disclosed.Rajawali Medika, based in Jakarta, was founded and managed by highly experienced professionals in sales and marketing of medical devices in the Asia Pacific region. The team's prior experience includes successful hands-on sales and marketing of sports medicine and arthroscopy products with J&J's DePuy Mitek division. Rajawali Medika has a strong network of key orthopaedic surgeons and sales distribution channels in South East Asian countries, experience in conducting professional education programmes and workshops, as well as experience in regulatory affairs to achieve speed to market.ChondroMimetic(R) is a minimally-invasive surgically placed scaffold for the repair of cartilage defects in the knee, backed by positive results of an eight-year clinical extension study reported in Q1 2018. The Company has made a submission for a CE Mark for ChondroMimetic(R) and is currently awaiting further feedback from the Notified Body reviewing the submission. The timing of the CE Mark approval is subject to a due process to be undertaken by the Regulatory Authority, and the previously stated timing of approval by the fiscal year end is therefore uncertain. ChondroMimetic(R) is not currently approved for sale in any markets.Jamal Rushdy, CEO, commented: "We are pleased to enter the partnership agreement with Rajawali Medika for Chondromimetic in South East Asia. We will benefit enormously from both their in-depth expertise in the area of sports medicine procedures as well as their regional presence. This agreement adds to other distributor agreements that we have been putting in place in Asia and Europe in order to initiate our launch of Chondromimetic soon after we obtain regulatory approval. We are currently awaiting feedback regarding our CE Mark submission and we will provide an update once new information becomes available and certainly no later than our proposed April trading update."Enquiries:Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Cenkos Securities Plc (Nominated Adviser and Broker) Steve Cox (Corporate Finance) Tel: 0207 397 8900 Giles Balleny Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Helen Cresswell Mob: 07841 917 679 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDUPDEAKFEDEKNEFF(END) Dow Jones NewswiresJanuary 31, 2019 02:00 ET (07:00 GMT)
moontheloon
21/1/2019
16:59
In 2016 they announced their target to increase revenue by 5 times in 5 years, from £3.24m in FY2016 to £16.2m in FY 2021. The fancy new target preceded a dilutive conditional placing, open offer and a private bond/warrants subscription. So how are they performing against their target? Well in the first 2 years they added £0.3m so in the next 3 years they’ll need to be adding £12.7m to the FY2018 3.5m revenue. In other words the target has gone from 5 times revenue in 5 years to 4.6 times revenue in 3 years which would be spectacular growth indeed. It could be time to get excited, unless you’re of a sceptical disposition.
gwr7
15/1/2019
08:06
Interesting RNS this morning continuing the run of positive news flow recently: Https://www.investegate.co.uk/collagen-sol-plc--cos-/rns/new-manufacturing-agreement/201901150700080666N/ A quick bit of research on Olaregen Therapeutix Inc revealed this transaction just one week ago: Https://www.businesswire.com/news/home/20190108005344/en/Generex-Biotechnology-Completes-Acquisition-Olaregen-Therapeutix
hyperboreus
07/1/2019
17:25
And news was leaking as share price bounce was before 3:45pm - But the regulators will do nothing as usual !! Still however well below my average selling price And where are they going to get the balance of the funds it appears they are required to invest under the terms of the grant - That is if I am reading the rns correctly "The grant totals GBP1.54m to support the Company's future investment of up to GBP3.96m across its next generation proprietary product development pipeline. "
pugugly
07/1/2019
17:00
So, it was the non-dilutive funding 😁
timbo003
07/1/2019
14:18
These are beginning to twitch, maybe news afoot on ChondroMimetic or the non-dilutive funding, or perhaps L&G are at last out.
timbo003
05/12/2018
18:29
There is a new Proactive video with Jamal and Hilary here: https://www.youtube.com/watch?v=qKfEZbiJ5vI
timbo003
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
ADVFN Advertorial
Your Recent History
LSE
COS
Collagen S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211018 22:43:17